Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022

Rhea-AI Summary

Aeglea BioTherapeutics (Nasdaq: AGLE) will participate in two key investor conferences in January 2022. The first is the 40th Annual J.P. Morgan Health Care Conference from January 10-13, with a live presentation by CEO Anthony G. Quinn on January 12 at 10:30 a.m. EST. The second is the H.C. Wainwright Bioconnect Virtual Conference, featuring an on-demand presentation by Quinn on January 10 at 7:00 a.m. EST. Aeglea focuses on developing human enzyme therapeutics for rare metabolic diseases, with lead candidate pegzilarginase in a Phase 3 trial and AGLE-177 in Phase 1/2 for Homocystinuria.

AUSTIN, Texas, Jan. 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows: 

Conference: 40th Annual J.P. Morgan Health Care Conference, January 10-13, 2022
Live Presentation Date/Time: Wednesday, January 12 at 10:30 a.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and CEO
Webcast: https://jpmorgan.metameetings.net/events/healthcare22/sessions/40001-aeglea-biotherapeutics/webcast?gpu_only=true&kiosk=true

Conference: H.C. Wainwright Bioconnect Virtual Conference, January 10-13, 2022
On Demand Presentation Date/Time: Monday, January 10 at 7:00 a.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and CEO
Webcast: https://journey.ct.events/view/ad45c7a4-33cb-482b-bf12-1cd993827823 

To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company's website. A replay of Company webcasts is archived on the website for 30 days following presentations.

About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in an ongoing Phase 3 pivotal trial in patients with Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy designations. Aeglea has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-two-investor-conferences-in-january-2022-301453721.html

SOURCE Aeglea BioTherapeutics, Inc.

FAQ

When will Aeglea BioTherapeutics participate in the J.P. Morgan Health Care Conference?

Aeglea BioTherapeutics will participate in the J.P. Morgan Health Care Conference from January 10-13, 2022, with a live presentation scheduled for January 12 at 10:30 a.m. EST.

Who will present at the H.C. Wainwright Bioconnect Virtual Conference?

CEO Anthony G. Quinn will present at the H.C. Wainwright Bioconnect Virtual Conference on January 10, 2022, at 7:00 a.m. EST.

What is the focus of Aeglea BioTherapeutics?

Aeglea BioTherapeutics focuses on developing human enzyme therapeutics for rare metabolic diseases.

What clinical trials is Aeglea currently conducting?

Aeglea is conducting a Phase 3 trial for pegzilarginase in Arginase 1 Deficiency and a Phase 1/2 trial for AGLE-177 targeting Homocystinuria.

Where can I access Aeglea's investor conference webcasts?

You can access Aeglea's investor conference webcasts on their website under the Events & Presentations section.